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Hyperglycemia and insulin resistance are key players in the development of atherosclerosis and its complications. A large bodyof evidence suggest
that metabolic abnormalities cause overproduction of reactive oxygen species (ROS). In turn, ROS, via endothelial dysfunction and inflammation,
play a major role in precipitating diabetic vascular disease. A better understanding of ROS-generating pathways may provide the basis to develop
novel therapeutic strategies against vascular complications in this setting. Part I of this review will focus on the most current advances in the patho-
physiologicalmechanismsof vasculardisease: (i) emerging roleof endothelium inobesity-induced insulin resistance; (ii) hyperglycemia-dependent
microRNAs deregulation and impairment of vascular repair capacities; (iii) alterations of coagulation, platelet reactivity, and microparticle release;
(iv) epigenetic-driven transcription of ROS-generating and proinflammatory genes. Taken together these novel insights point to the development
of mechanism-based therapeutic strategies as a promising option to prevent cardiovascular complications in diabetes.
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Introduction
The number of people with diabetes mellitus is alarmingly increasing
due to the growing prevalence of obesity, genetic susceptibility, ur-
banization, and ageing.1,2
Type 2 diabetes, the most common form of the disease, may remain
undetected for many years and its diagnosis is often made incidentally
through an abnormal blood or urine glucose test. Hence, physicians
often face this disease at an advanced stage when vascular complica-
tions have already occurred in most ofpatients.Macrovascular compli-
cations are mainly represented by atherosclerotic disease and its
sequelae. Diabetes-related microvascular disease such as retinopathy
andnephropathyaremajorcausesofblindnessand renal insufficiency.1
Based on this scenario, a better understanding of the mechanisms
underlying diabetic vascular disease is mandatory because it may
provide novel approaches to prevent or delay the development of
its complications.This reviewwill focuson themostcurrent advances
in the pathophysiology of vascular disease (Part I) and will address
clinical manifestations and management strategies of patients with
diabetes (Part II).
Hyperglycemia, oxidative stress,
and vascular disease
The alterations in vascular homeostasis due to endothelial and
smooth muscle cell dysfunction are the main features of diabetic
vasculopathy favouring a pro-inflammatory/thrombotic state
which ultimately leads to atherothrombosis. Macro- and micro-
vascular diabetic complications are mainly due to prolonged expos-
ure to hyperglycemia clustering with other risk factors such as
arterial hypertension, dyslipidemia as well as genetic susceptibility.3
Interestingly, nephropathy, retinopathy, and diabetic vascular
disease are in line with the notion that endothelial, mesangial, and
retinal cells are all equipped to handle high sugar levels when com-
pared with other cell types.4 The detrimental effects of glucose
already occur with glycemic levels below the threshold for the
diagnosis of diabetes. This is explained by the concept of ‘glycemic
continuum’ across the spectrum of prediabetes, diabetes, and cardio-
vascular risk.5–8 Early disglycemia caused by obesity-related insulin re-
sistance or impaired insulin secretion is responsible for functional and
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structural alterations of the vessel wall culminating with diabetic vascular
complications.
The initial trigger whereby high glucose concentrations alter vas-
cular function is the imbalance between nitric oxide (NO) bioavail-
ability and accumulation of reactive oxygen species (ROS), leading
to endothelial dysfunction.9 Indeed, hyperglycemia-induced gener-
ation of superoxide anion (O2
2) inactivatesNO to form peroxynitrite
(ONOO2), a powerful oxidant which easily penetrates across
phospholipid membranes and induces substrate nitration.9 Protein
nitrosylation blunts activity of antioxidant enzymes and endothelial
NO synthase10 (eNOS, Figure 1). Importantly, reduced NO bioavail-
ability is a strong predictor of cardiovascular outcomes.10,11
Overproduction of ROS by mitochondria is considered as a causal
link between elevated glucose and the major biochemical pathways
involved in the development of vascular complications of diabetes.12
Indeed, hyperglycemia-induced ROS production triggers several cel-
lularmechanisms includingpolyol andhexosamine flux, advancedgly-
cation end products (AGEs), protein kinase C (PKC) activation, and
NF-kB-mediated vascular inflammation.12,13 One of the main sources
of ROS in the setting of hyperglycemia is represented by PKC and its
downstream targets. The hyperglycemic environment induces a
chronic elevation of diacyglycerol levels in endothelial cells with sub-
sequent membrane translocation of conventional (a, b1, b2) and
non-conventional (d) PKC isoforms. Once activated, PKC is respon-
sible for different structural and functional changes in the vasculature
including alterations in cellular permeability, inflammation, angiogen-
esis, cell growth, extracellular matrix expansion, and apoptosis.14 An
important consequence of PKC activation is ROS generation. In vas-
cular endothelial cells, hyperglycemia-induced activation of PKC
increases superoxide production via NADPH oxidase15 (Figure 1).
Indeed, treatment with a PKCb inhibitor suppresses NADPH-
dependent ROS generation.16
More recently, it has been reported that glucose-induced activa-
tion of PKC b2 isoform phosphorylates p66
Shc at serine 36 leading
to its translocation to the mitochondria, cytochrome c oxidation
and accumulation of ROS into the organelle.17,18 The p66Shc
adaptor protein functions as a redox enzyme implicated in mito-
chondrial ROS generation and translation of oxidative signals into
apoptosis.17 Interestingly, diabetic p66Shc2/2 mice are protected
against hyperglycemia-induced endothelial dysfunction and oxidative
Figure 1 Mechanisms of hyperglycemia-induced vascular damage. High intracellular glucose concentrations lead to PKC activation and subse-
quent ROS production by NADPH oxidase and p66Shc adaptor protein. Increased oxidative stress rapidly inactivates NO leading to formation
of the pro-oxidant ONOO2 responsible for protein nitrosylation. Reduced NO availability is also due to PKC-dependent eNOS deregulation.
Indeed, PKC triggers enzyme up-regulation thus enhancing eNOS uncoupling and leading to a further accumulation of free radicals. On the
other hand, hyperglycemia reduces eNOS activity blunting activatory phosphorylation at Ser1177. Together with the lack of NO, glucose-induced
PKC activation causes increased synthesis of ET-1 favouring vasoconstriction and platelet aggregation. Accumulation of superoxide anion also trig-
gers up-regulation of pro-inflammatory genes MCP-1, VCAM-1, and ICAM-1 via activation of NF-kB signalling. These events lead to monocyte ad-
hesion, rolling, and diapedesis with formation of foam cells in the sub-endothelial layer. Foam cell-derived inflammatory cytockines maintain vascular
inflammationaswell as proliferation of smooth muscle cells, accelerating the atherosclerotic process. Endothelial dysfunction in diabetes also derives
from increased synthesis of TXA2 via up-regulation of COX-2 and inactivation of PGIS by increased nitrosylation. Furthermore, ROS increase the
synthesisof glucosemetabolite methylglyoxal leading toactivationofAGE/RAGEsignalling and thepro-oxidanthexosamineandpolyolpathwayflux.
PKC, protein kinase C; eNOS, endothelial nitric oxide synthase; ET1, endothelin 1; ROS, reactive oxygen species; NO, nitric oxide; MCP-1, mono-
cyte chemoattractant protein-1; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intracellular cell adhesion molecule-1; AGE, advanced glyca-
tion end product.
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stress.19 The relevance of p66Shc in the clinical setting of diabetes is
supported by the notion that p66Shc gene expression is increased
in peripheral blood mononuclear cells obtained from patients with
type 2 diabetes and correlates with plasma 8-isoprostane levels, an
in vivo marker of oxidative stress.20 Moreover, p66Shc protein has re-
cently emerged as an upstream modulator of NADPH activation
further strengthening its pivotal role in ROS generation.21,22
PKC affects NO availability not only via intracellular accumulation
of ROS but also by decreasing eNOS activity.23– 25 PKC also leads to
increased production of endothelin-1 (ET-1) favouring vasoconstric-
tion and platelet aggregation14 (Figure 1). The role of ET-1 in the
pathophysiologyof diabetic complications is confirmed by the obser-
vation that the activity of endogenous ET-1 on ET(A) receptors is
enhanced in the resistance vessels of patients with diabetes.26
In the vessel wall, PKC-dependent ROS production also partici-
pates in the atherosclerotic process by triggering vascular inflamma-
tion.13,27 Indeed,ROS lead toup-regulationandnuclear translocation
of NF-kB subunit p65 and, hence, transcription of pro-inflammatory
genes encoding for monocyte chemoattractant protein-1 (MCP-1),
selectins, vascular cell adhesion molecule-1 (VCAM-1), and intracel-
lular cell adhesion molecule-1 (ICAM-1). This latter event facilitates
adhesion of monocytes to the vascular endothelium, rolling, and dia-
pedesis in the sub-endothelium with subsequent formation of foam
cells (Figure 1). Secretion of IL-1 and TNF-a from active macrophages
maintains up-regulation of adhesion molecules by enhancing NF-kB
signalling in the endothelium and also promotes smooth muscle
cells growth and proliferation10 (Figure 1). Consistently, inhibition
of PKCb2 isoform blunts VCAM-1 up-regulation in human endothe-
lial cells upon glucose exposure.27
Endothelial dysfunction in diabetes is not only the result
of impaired NO availability but also of increased synthesis of vaso-
contrictors and prostanoids.10 PKC-mediated cyclooxygenase-2
(COX-2) up-regulation is associated with an increase of thromb-
oxane A2 and a reduction of prostacyclin (PGI2) release28
(Figure 1). These findings suggest that PKC is the upstream signalling
molecule affecting vascular homeostasis in the setting of hypergly-
cemia28 (Figure 1). Mitochondrial ROS also increase intracellular
levels of the glucose metabolite methylglyoxal and AGEs synthe-
sis.12,29,30 In experimental diabetes, methylglyoxal is a key player in
the pathophysiology of diabetic complications through oxidative
stress, AGEs accumulation, and endothelial dysfunction.29,31 Gener-
ation of AGEs leads to cellular dysfunction by eliciting activation of
the AGEs receptor (RAGE).30,32 AGE-RAGE signalling in turn acti-
vates ROS-sensitive biochemical pathways such as the hexosamine
flux.13 In the hyperglycemic environment, an increased flux of
fructose-6-phosphate activates a cascade of events resulting in dif-
ferent glycosilation patterns which are responsible for deregulation
of enzymes involved in vascular homeostasis. Specifically, O-
GlcNAcylation at the Akt site of eNOS protein leads to reduced
eNOS activity and endothelial dysfunction.13,33 Moreover, glycosyla-
tion of transcription factors causes up-regulation of inflammatory
(TGFa, TGFb1) and pro-thrombotic genes (plasminogen activator
inhibitor-1).33,34 Glucose induced-ROS production also activates
the polyol pathway flux involved in vascular redox stress.12,35 Ac-
cordingly, hyperactivation of this pathway has been associated with
increased atherosclerotic lesions in diabetic mice.36
Insulin resistance
and atherothrombosis
Insulin resistance is a major feature of type 2 diabetes and develops in
multiple organs, including skeletal muscle, liver, adipose tissue, and
heart.37 The onset of hyperglycemia and diabetes is often preceded
by many years of insulin resistance. Obesity plays a pivotal role in
this phenomenon providing an important link between type 2 dia-
betes and fat accumulation.38 Indeed, a substantial proportion of dia-
betic patients are obese.39 Obesity is a complex disorder leading to
alterations in lipid metabolism, deregulation of hormonal axes, oxida-
tive stress, systemic inflammation, and ectopic fat distribution.
Adipose tissue is an active source of inflammatory mediators and
free fatty acids (FFAs).40 Accordingly, obese patients with type 2 dia-
betesdisplay increased plasma levels of inflammatorymarkers.41 Free
fatty acids bind Toll-like receptor (TLR) activating NF-kB through
degradation of the inhibitory complex IkBa by IKKb-kinase.42 As a
result, NF-kB triggers tissue inflammation due to up-regulation of in-
flammatory genes IL-6 and TNF-a.
Toll-like receptor activation by FFA leads to phosphorylation of
insulin receptor substrate-1 (IRS-1) by c-Jun amino-terminal kinase
(JNK) and PKC, thereby altering its ability to activate downstream
targets PI3-kinase and Akt. These molecular events result in the
down-regulation of the glucose transporter GLUT-4 and, hence,
insulin resistance43 (Figure 2). Insulin resistance is critically involved
in vascular dysfunction in subjects with type 2 diabetes.42 Indeed,
down-regulation of PI3-kinase/Akt pathway leads to eNOS inhibition
and decreased NO production.44 Together with reduced NO syn-
thesis, intracellular oxidation of stored FFA generates ROS leading
to vascular inflammation, AGEs synthesis, reduced PGI2 synthase ac-
tivity, and PKC activation13,44 (Figure 2).
Increased ROS levels associated with insulin resistance scavenge
NO production and produce peroxynitrite, with a further reduction
of NO bioavailability. Reduced cellular levels of NO facilitate
pro-inflammatory pathways triggered by increased cytokine produc-
tion. Indeed, TNF-a and IL-1 increase NF-kB activity and expression
of adhesion molecules. TNF-a also stimulates the expression of C-
reactive protein which down-regulates eNOS and increases the pro-
duction of adhesion molecules and endothelin-1.26,42 A recent study
clearly demonstrated that loss of insulin signalling in the vascular
endothelium leads to endothelial dysfunction, expression of adhe-
sion molecules, and atherosclerotic lesions in mice.45
Although insulin resistance development has been attributed to
adipocyte-derived inflammation, recent evidence is overturning the
adipocentric paradigm.43 Indeed, inflammation and macrophage acti-
vation seem to primarily occur in non-adipose tissue in obesity.46,47
This concept is supported by the notion that suppression of inflam-
mation in the vasculature prevents insulin resistance in other
organs and prolongs lifespan.48 Consistently, transgenic mice with
endothelium-specific overexpression of the inhibitory NF-kB
subunit IkBawere protected from the development of insulin resist-
ance. In these mice, obesity-induced macrophage infiltration of
adipose tissue and plasma oxidative stress markers were reduced
whereas blood flow, muscle mitochondrial content, and locomotor
activity were increased, confirming the pivotal role of the transcrip-
tion factor NFkB in oxidative stress, vascular dysfunction, and inflam-
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Figure 2 Insulin resistance as trigger of atherothrombosis. In subjects with obesity or type 2 diabetes the increase in FFA activates TLR leading
NF-kB nuclear translocation and subsequent up-regulation of inflammatory genes IL-6 and TNF-a. On the other hand, JNK and protein kinase C
phosphorylate insulin receptor substrate-1 (IRS-1), thus blunting its downstream targets PI3-kinase and Akt. This results in down-regulation of
glucose transporter GLUT-4 and, hence, insulin resistance. Impaired insulin sensitivity in the vascular endothelium leads to increased FFA oxidation,
ROS formation, and subsequent activation of detrimental biochemical pathways such as AGE synthesis, PKC activation, protein glicosylation as well
as down-regulation of PGI2. These events blunt eNOS activity thereby leading to endothelial dysfunction. Lackof insulin signalling in platelets impairs
the IRS1/PI3K pathway resulting in Ca2+ accumulation and increased platelet aggregation. FFA, free fatty acids; TLR, toll-like receptor; JNK, c-Jun
amino-terminal kinase; IRS-1, Insulin receptor substrate-1; NO, nitric oxide; eNOS, endothelial nitric oxide shyntase; IL-6, interleukin-6; TNF-a,
tumor necrosis factor.
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mation.48 Another study confirmed these findings, showing that
genetic disruption of the insulin receptor substrate 2 (IRS-2) in endo-
thelial cells reduces glucose uptake by skeletal muscle.49 These novel
findings strengthen the central role of endothelium in obesity-
induced insulin resistance, suggesting that blockade of vascular in-
flammation and oxidative stress may be a promising approach to
prevent metabolic disorders. Notably, pharmacological improve-
ment in insulin sensitivity in patients with type 2 diabetes and meta-
bolic syndrome is associated with restoration of flow-mediated
vasodilation.50– 52
The atherogenic effects of insulin resistance are also due to
changes in lipid profile such as high triglycerides, low HDL choles-
terol, increased remnant lipoproteins, elevated apolipoprotein B
(ApoB) as well as small and dense LDL.53 Once circulating FFA
reach the liver, very low density lipoprotein (VLDL) are assembled
and made soluble by increased synthesis of ApoB. VLDL are pro-
cessed bycholesteryl ester transfer protein allowing transferof trigly-
cerides to LDL, which become small and dense and, hence, more
atherogenic. Atherogenic dyslipidemia is a reliable predictor of car-
diovascular risk and its pharmacological modulation reduces vascular
events in subjects with type 2 diabetes and metabolic syndrome.54–56
Coronaryevents in patients with insulin resistance are triggered by
virtue of a prothrombotic state. Under physiological conditions,
insulin inhibits platelet aggregation and thrombosis via tissue factor
(TF) inhibition and enhanced fibrinolytic action due to modulation
of plasminogen activator inhibitor-1 (PAI-1) levels. Indeed, patients
with acute myocardial infarction receiving fibrinolityic therapy plus
48 h insulin infusion displayed a marked decrease in PAI-1 levels.57
In contrast, insulin resistance facilitates atherothrombosis through
increased cellular synthesis of PAI-1 and fibrinogen and reduced pro-
duction of tissue plasminogen activator. In platelets, lack of insulin
leads to a down-regulation of the IRS-1/Akt pathway resulting in
calcium accumulation upon basal conditions58 (Figure 2). This latter
mechanism may explain why platelets from diabetic patients show
faster response and increased aggregation compared with those
from healthy subjects.59 Moreover, platelet reactivity and excretion
of tromboxane metabolites are increased in obese patients with
insulin resistance and this phenomenon is reversed by weight loss
or 3-week treatment with pioglitazone.60 Body weight as well as
impaired insulin sensitivity may also account for the faster recovery
of cyclooxygenase activity despite aspirin treatment.61 Indeed,
higher body mass index was an independent predictor of inadequate
suppression of tromboxane biosynthesis in non-diabetics subjects
treated with aspirin.61 In this study, the increase of aspirin dosage
was sufficient to warrant platelet inhibition. This clinical observation
may explain the residual cardiovascular risk in obese patients treated
with anti-platelet medications.
Hyperglycemia and insulin resistance alone may not explain the
persistent cardiovascular risk burden associated with type 2 diabetes.
Indeed, normalization of glycemia does not reduce macrovascular
events suggesting that mediators of vascular risk other than glucose
significantly participate to increase the residual cardiovascular risk
in diabetic patients.62 In this regard, adipose tissue dysfunction, in-
flammation, and aberrant adipokine release may be particularly rele-
vant.63 In patients with abdominal obesity, an increased lipid storage
leads to hypoxia, chronic inflammation together with changes in the
cellular components of adipose tissue, leading to an altered secretory
profile. Adipokines linked to vascular disease are leptin, adipocyte
fatty acid-binding protein, interleukins, and novel ones like lipocalin-2
and pigment epithelium-derived factor. These molecules may drive
vascular dysfunction via increased proliferation/migration of
smooth muscle cells, eNOS inhibition, and activation of NFkB signal-
ling with subsequent expression of adhesion molecules and athero-
sclerosis.64 Future work will need to address the potential role of
these molecules as biomarkers and/or drug targets.
MicroRNA and diabetic
vascular disease
MicroRNAs (miRs) are a newly identified class of small non-coding
RNAs emerging as key players in the pathogenesis of hypergly-
cemia-induced vascular damage.65,66 These small non-coding RNAs
orchestrate different aspects of diabetic vascular disease by regulat-
ing gene expression at the post-transcriptional level. Microarray
studies have shown an altered profile of miRs expression in subjects
with type 2 diabetes.67– 69 Indeed, diabetic patients display a signifi-
cant deregulation of miRs involved in angiogenesis, vascular repair,
and endothelial homeostasis.67 Over the last few years, different
studies have explored the mechanisms whereby deregulation of
miRs expression may contribute to vascular disease in subjects
with diabetes. In endothelial cells exposed to high glucose miR-320
is highly expressed and targets several angiogenic factors and their
receptors, including vascular endothelial growth factor and insulin-
like growth factor-1 (IGF-1). Elevated levels of this miR are associated
with decreased cell proliferation and migration, while its down-
regulation restores these properties and increases IGF-1 expression,
promoting angiogenesis and vascular repair70 (Figure 3).
Hyperglycemia also increases the expression of miR-221, a regula-
tor of angiogenesis targeting c-kit receptor which is responsible for
migration and homing of endothelial progenitor cells (EPCs).71
miR-221 and 222 were also found to mediate AGE-induced vascular
damage.72 Indeed, down-regulation of miR-222 both in human endo-
thelial cells exposed to high glucose and in diabetic mice elicits
AGE-related endothelial dysfunction via targeting, cyclin-dependent
kinase proteins involved in cell cycle inhibition (P27KIP1 and
P57KIP2).72 A recent study demonstrated that miR-503 is critically
involved in hyperglycemia-induced endothelial dysfunction in diabet-
ic mice and is up-regulated in ischaemic limb muscles of diabetic sub-
jects.73 The detrimental effects of miR-503 in the setting of diabetes
have been explained by its interaction with CCNE and cdc25A, crit-
ical regulators of cell cycle progression affecting endothelial cell mi-
gration and proliferation. Interestingly, miR-503 inhibition was able
to normalize post-ischaemic neovascularization and blood flow re-
covery in diabetic mice. These findings provide the rationale to
foresee a protective effect of the modulation of miR-503 expression
against diabetic vascular complications.
Plasma miR profiling showed a profound down-regulation of
miR-126 in a cohort of diabetic patients.67 Recent evidence suggest
that reduced miR-126 expression levels are partially responsible
for impaired vascular repair capacities in diabetes.74,75 miR-126 ex-
pression was reduced in EPCs isolated from diabetics and transfec-
tion with anti-miR-126 blunted EPCs proliferation and
migration.74,75 In contrast, restored expression of this miR promoted
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EPCs-related repair capacities and inhibited apoptosis. miR-126 role
in EPCs function is mediated by Spred-1, an inhibitor of Ras/ERK sig-
nalling pathway, a critical regulator of cell cycle.
Collectively, these studies support the notion that miRs drive
complex signalling networks by targeting the expression of genes
involved in cell differentiation, migration, and survival.
Thrombosis and coagulation
Individuals affected by diabetes display an increased risk of coronary
events and cardiovascular mortality when compared with non-
diabetic subjects.76 –78 This phenomenon is largely explained by a
deregulation of factors involved in coagulation and platelet activa-
tion.79,80 Both insulin resistance and hyperglycemia participate to
the pathogenesis of this prothrombotic state.81 Insulin resistance
increases PAI-1 and fibrinogen and reduces tissue plasminogen
activator levels. The largest increase in PAI-1 has been reported
in diabetic patients with poor glycemic control and treatment
with glucose-lowering agents glipizide or metformin comparably
decreased PAI-1.82 Hyperinsulinemia induces TF expression in
monocytes of patients with type 2 diabetes leading to increased TF
procoagulant activity and thrombin generation.83 These events are
enhanced by hyperglycemia83,84 (Figure 4). Low-grade inflammation
induces TF expression also in the vascular endothelium of diabetic
subjects contributing to atherothrombosis.81,83
Microparticles (MPs), vescicles released in the circulation from
various cell types following activation or apoptosis, are increased in
diabetic patients and predict cardiovascular outcome.85,86 Micropar-
ticles from patients with type 2 diabetes have shown to increase co-
agulation activity in endothelial cells85 (Figure 4). Moreover, MPs
carrying TF promote thrombus formation at sites of injury represent-
ing a novel and additional mechanisms of coronary thrombosis in dia-
betes.85
Among the factors contributing to the diabetic prothrombotic
state, platelet hyperreactivity is of major relevance.87 A number of
mechanisms contribute to platelet dysfunction affecting adhesion, ac-
tivation as well as aggregation phases of platelet-mediated throm-
bosis (Figure 4). Hyperglycemia alters platelet Ca2+ homeostasis
leading to cytoskeleton abnormalities and increased secretion of
proaggregant factors.58 Moreover, up-regulation of glycoproteins
Ib and IIb/IIIa in diabetic patients triggers thrombus via interacting
with Von Willebrand factor (vWF) and fibrin molecules (Figure 4).
Figure 3 MicroRNAs involved in diabetic vascular disease. Schematic representation of microRNAs and their relative targets contributing to
reduced vascular repair and, hence, diabetes-related vascular dysfunction. VEGF, vascular endothelial growth factor; IGF-1, insulin-like growth
factor-1; ECs, endothelial cells; AGEs, advanced glycation end-products.
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Vascular hyperglycemic memory
Recent prospective clinical trials have shown that normalization of
glycemia failed to reduce cardiovascular burden in the diabetic
population.88–91 In these trials, intensive glucose-lowering therapy
was started after a median duration of diabetes ranging from 8 to
11 years.88– 91 In contrast, early treatment of hyperglycemia was
shown to be beneficial.92,93 These findings support the concept
that hyperglycemic environment may be remembered in the
vasculature. Reactive oxygen species are probably involved in this
phenomenon.94,95
The persistence of hyperglycemic stress despite blood glucose
normalization has recently been defined ‘hyperglycemic memory’.
A substantial understanding of its mechanisms has been achieved
only in recent years.96,97 It has been recently demonstrated that tran-
sient hyperglycemia activates NF-kB, and this effect persists despite
subsequent normalization of glucose levels. This finding is explained
by epigenetic changes occurring at the level of DNA and histone-
binding promoter of pro-oxidant and pro-inflammatory genes.
Specifically, methylation and acetylation are critical epigenetic
mark modulated by the hyperglycemic environment. Methylation
of p65/NFkB promoter by the ROS-dependent methyltransferase
Set7/9 is indeed the mechanisms whereby vascular inflammation is
not reverted by restoration of normoglycemia98 (Figure 5). We
have recently identified the source of ROS perpetuating vascular dys-
function despite normoglycemia restoration.18
In diabetic mice and human endothelial cells, glucose normaliza-
tion did not revert up-regulation of p66Shc protein, a mitochondrial
adaptor critically involved in ROS generation.18 Persistent p66Shc
expression is driven by epigenetic changes as reduced promoter
methylation and acetylation of histone 3 (Figure 5). Moreover,
p66Shc-dependent ROS generation maintains up-regulation of
PKCbII and inhibits eNOS activity, thus feeding a detrimental
vicious cycle despite restoration of normoglycemia18 (Figure 5). Per-
sistent oxidative stress is also responsible for sustained vascular
apoptosis via caspase 3 activation. Gene silencing of p66Shc blunted
persistent endothelial dysfunction and oxidative stress in the vascu-
lature of diabetic mice, suggesting that this protein drives hypergly-
cemic memory18 (Figure 5). In addition, other studies have shown
that both mammalian deacetylase SIRT-1 and tumour suppressor
p53 have a strong memory effect despite glucose normalization.99,100
Interestingly enough, these findings are in line with the notion that
both SIRT-1 and p53 control p66Shc transcription.101,102 Indeed,
reduced SIRT-1 activity in diabetes favours acetylation of histone
3-binding p66Shc promoter. Moreover, increased p53 activity main-
tains p66Shc memory effect (Figure 5).101,102 All together, these path-
ways might be involved in self-perpetuating vascular damage of
patients with diabetes despite optimal glycemic control.
Figure 4 Coagulation and platelet reactivity in diabetes. In patients with diabetes chronic hyperglycemia and insulin resistance determine a sig-
nificant alteration in the coagulation factors as well as increased platelet aggregation, leading to a prothrombotic state. Diabetes-induced increase
of TF levels activates thrombin converting fibrinogen into fibrin. Fibrin organization is further enhanced due to high PAI-1 and reduced t-PA levels.
Increased Ca2+ content, thrombin stimulation as well as interaction with vWF via gpIIb/IIIa receptor lead to platelet shape change, granule release,
and aggregation. Release of MPs from injured endothelium and circulating platelets contribute to accelerate thrombus development. Endothelial
dysfunction precipitates rupture of the endothelial layer leading to exposure of collagen and vWF thereby activating platelets and favouring vascular
thrombosis. TF, tissue factor; t-PA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor -1; MPs, microparticles; vWF, vonWillebrand
factor; ECs, endothelial cells.
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Future perspectives
Oxidative stress plays a major role in the development of micro- and
macrovascular complications. Accumulation of free radicals in the
vasculature of diabetic patients is responsible for the activation of
detrimental biochemical pathways, miRs deregulation, release of
MPs, and epigenetic changes contributing to vascular inflammation
and ROS generation. Since cardiovascular risk burden is not eradi-
cated by intensive glycemic control associated with optimal multifac-
torial treatment, mechanism-based therapeutic strategies are in
highly demand.88– 91 Specifically, inhibition of key enzymes involved
in hyperglycemia-induced vascular damage or activation of pathways
improving insulin sensitivity may represent promising approaches.
Modulation of specific miRs might contribute to improve EPC-
driven vascular repair. Moreover, the progressive identification of a
complex scenario driven by epigenetic changes that modulate tran-
scription of ROS-generating and pro-inflammatory genes may repre-
sent an attractive opportunity to dampen oxidative stress, vascular
inflammation, and hence to prevent cardiovascular complications in
patients with diabetes.
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